ImmunityBio, Inc. $IBRX Position Boosted by SBI Securities Co. Ltd.

SBI Securities Co. Ltd. boosted its holdings in ImmunityBio, Inc. (NASDAQ:IBRX) by 45.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 198,491 shares of the company’s stock after purchasing an additional 62,170 shares during the period. SBI Securities Co. Ltd.’s holdings in ImmunityBio were worth $1,874,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the business. BlackRock Inc. grew its stake in shares of ImmunityBio by 29.4% during the second quarter. BlackRock Inc. now owns 34,083,262 shares of the company’s stock valued at $298,399,000 after buying an additional 7,736,819 shares during the last quarter. State Street Corp lifted its stake in shares of ImmunityBio by 20.8% in the 2nd quarter. State Street Corp now owns 21,398,438 shares of the company’s stock valued at $187,343,000 after acquiring an additional 3,690,335 shares during the last quarter. Bank of America Corp DE bought a new stake in shares of ImmunityBio in the 2nd quarter valued at about $19,125,000. SEB Asset Management AB bought a new stake in shares of ImmunityBio in the 1st quarter valued at about $18,770,000. Finally, Private Advisor Group LLC boosted its holdings in ImmunityBio by 923.5% during the 1st quarter. Private Advisor Group LLC now owns 1,648,556 shares of the company’s stock valued at $12,644,000 after acquiring an additional 1,487,482 shares during the period. 8.58% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on IBRX shares. HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of ImmunityBio in a research report on Thursday, October 15th. Piper Sandler reiterated an “overweight” rating and issued a $16.00 price objective on shares of ImmunityBio in a research report on Wednesday, October 14th. Jefferies Financial Group increased their price objective on ImmunityBio from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, October 14th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of ImmunityBio in a research note on Tuesday, October 6th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.00.

Insider Buying and Selling

In other news, Director Barry Simon sold 25,000 shares of ImmunityBio stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $10.75, for a total value of $268,750.00. Following the sale, the director directly owned 2,777,788 shares in the company, valued at approximately $29,861,221. This trade represents a 0.89% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Cheryl Cohen sold 81,056 shares of the business’s stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $10.50, for a total value of $851,088.00. Following the transaction, the director directly owned 100,309 shares in the company, valued at $1,053,244.50. This trade represents a 44.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 66.10% of the stock is currently owned by company insiders.

ImmunityBio Price Performance

NASDAQ IBRX opened at $8.22 on Friday. ImmunityBio, Inc. has a 1 year low of $1.95 and a 1 year high of $12.43. The stock has a market capitalization of $8.71 billion, a PE ratio of -8.47 and a beta of 0.02. The business’s 50-day moving average is $8.65 and its 200 day moving average is $8.01.

ImmunityBio (NASDAQ:IBRX) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14). The business had revenue of $51.24 million during the quarter, compared to analyst estimates of $49.70 million. As a group, equities research analysts anticipate that ImmunityBio, Inc. will post -0.30 earnings per share for the current year.

ImmunityBio Profile

ImmunityBio, Inc is a biotechnology company focused on developing and commercializing immunotherapies designed to activate and strengthen the body’s immune response against cancer and infectious diseases. The company’s approach combines immune-system modulators, cellular therapies, vaccines and other technologies intended to address multiple stages of the disease-treatment process.

Its lead product, Anktiva (nogapendekin alfa inbakicept-pmln, also known as N-803), is an interleukin-15 receptor agonist designed to stimulate natural killer cells and T cells.